Dopaminergic drugs in congestive heart failure

Hemodynamic and neuroendocrine responses to ibopamine, dopamine, and dihydroergotoxine

Marco Metra, Cristina Missale, Pier Franco Spano, Livio Dei Cas

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Ibopamine has hemodynamic and neurohumoral effects potentially useful for the treatment of congestive heart failure (CHF), but its mechanism of action is not completely clear. To evaluate the role of dopaminergic receptor stimulation in the hemodynamic and neurohumoral activity of ibopamine, we compared the effects of ibopamine, 100 mg orally (p.o.) with those of dopamine 2, 4, and 6 μg/kg/min intravenously (i.v.) and of the DA2 agonist dihydroergotoxine 6 μg/kg i.v. in 13 patients with chronic CHF [left ventricular ejection fraction (LVEF) ±35%]. All patients underwent right heart Swan-Ganz catheterization with determination of hemodynamic parameters at baseline, after 30 min of infusion of each dose of dopamine (DA) and ±6 h after ibopamine and dihydroergotoxine administration. Blood samples for the assessment of plasma renin activity (PRA), aldosterone, norepinephrine (NE), and epinephrine (Epi) were also obtained. Ibopamine induced a peak 21% increase of cardiac index (CI) with a 23 and 25% increase in stroke volume (SV) and stroke work indexes (SWI), respectively, and an 18% reduction in systemic vascular resistance (SVR). Similar changes were observed after DA infused at the doses of 2 and 4 μg/kg/min, whereas with the dose of 6 μg/kg/min heart rate (HR) increased by 23% and SV index (SVI) did not change further. Dihydroergotoxine administration induced only a significant 9% decrease in mean arterial pressure (MAP), with a 13% reduction in SVR. Plasma NE levels were reduced by 24% after ibopamine and by 20% after dihydroergotoxine; in contrast, DA did not significantly change NE levels at the doses of 2 and 4 μg/kg/min and increased them at 6 μg/kg/min. Plasma aldosterone levels were significantly decreased by all three agents. The effects of ibopamine on systemic hemodynamics are similar to those of DA infused at 2-4 μg/kg/min, whereas the DA2 agonist dihydroergotoxine reduced arterial pressure and SVR. Plasma aldosterone levels were decreased by all three agents, whereas plasma NE levels were reduced by ibopamine and dihydroergotoxine but not by DA. Therefore, hemodynamic effects of ibopamine probably can be ascribed mainly to the stimulation of DA1 and DA2 receptors, whereas its neuroendocrine effects are produced by DA2 receptor stimulation.

Original languageEnglish
Pages (from-to)732-740
Number of pages9
JournalJournal of Cardiovascular Pharmacology
Volume25
Issue number5
Publication statusPublished - 1995

Fingerprint

Dihydroergotoxine
Dopamine Agents
Dopamine
Heart Failure
Hemodynamics
Norepinephrine
Aldosterone
Vascular Resistance
Stroke Volume
Arterial Pressure
Swan-Ganz Catheterization
ibopamine
Patient Rights
Cardiac Catheterization
Renin
Epinephrine
Heart Rate
Stroke

Keywords

  • Congestive heart failure
  • DA2 receptor stimulation
  • Dihydroergotoxine
  • Dopamine
  • Ibopamine
  • Norepinephrine
  • Systemic hemodynamics

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Pharmacology

Cite this

Dopaminergic drugs in congestive heart failure : Hemodynamic and neuroendocrine responses to ibopamine, dopamine, and dihydroergotoxine. / Metra, Marco; Missale, Cristina; Franco Spano, Pier; Dei Cas, Livio.

In: Journal of Cardiovascular Pharmacology, Vol. 25, No. 5, 1995, p. 732-740.

Research output: Contribution to journalArticle

Metra, Marco ; Missale, Cristina ; Franco Spano, Pier ; Dei Cas, Livio. / Dopaminergic drugs in congestive heart failure : Hemodynamic and neuroendocrine responses to ibopamine, dopamine, and dihydroergotoxine. In: Journal of Cardiovascular Pharmacology. 1995 ; Vol. 25, No. 5. pp. 732-740.
@article{db7dfe593e704d509e1ca6e949aac8c9,
title = "Dopaminergic drugs in congestive heart failure: Hemodynamic and neuroendocrine responses to ibopamine, dopamine, and dihydroergotoxine",
abstract = "Ibopamine has hemodynamic and neurohumoral effects potentially useful for the treatment of congestive heart failure (CHF), but its mechanism of action is not completely clear. To evaluate the role of dopaminergic receptor stimulation in the hemodynamic and neurohumoral activity of ibopamine, we compared the effects of ibopamine, 100 mg orally (p.o.) with those of dopamine 2, 4, and 6 μg/kg/min intravenously (i.v.) and of the DA2 agonist dihydroergotoxine 6 μg/kg i.v. in 13 patients with chronic CHF [left ventricular ejection fraction (LVEF) ±35{\%}]. All patients underwent right heart Swan-Ganz catheterization with determination of hemodynamic parameters at baseline, after 30 min of infusion of each dose of dopamine (DA) and ±6 h after ibopamine and dihydroergotoxine administration. Blood samples for the assessment of plasma renin activity (PRA), aldosterone, norepinephrine (NE), and epinephrine (Epi) were also obtained. Ibopamine induced a peak 21{\%} increase of cardiac index (CI) with a 23 and 25{\%} increase in stroke volume (SV) and stroke work indexes (SWI), respectively, and an 18{\%} reduction in systemic vascular resistance (SVR). Similar changes were observed after DA infused at the doses of 2 and 4 μg/kg/min, whereas with the dose of 6 μg/kg/min heart rate (HR) increased by 23{\%} and SV index (SVI) did not change further. Dihydroergotoxine administration induced only a significant 9{\%} decrease in mean arterial pressure (MAP), with a 13{\%} reduction in SVR. Plasma NE levels were reduced by 24{\%} after ibopamine and by 20{\%} after dihydroergotoxine; in contrast, DA did not significantly change NE levels at the doses of 2 and 4 μg/kg/min and increased them at 6 μg/kg/min. Plasma aldosterone levels were significantly decreased by all three agents. The effects of ibopamine on systemic hemodynamics are similar to those of DA infused at 2-4 μg/kg/min, whereas the DA2 agonist dihydroergotoxine reduced arterial pressure and SVR. Plasma aldosterone levels were decreased by all three agents, whereas plasma NE levels were reduced by ibopamine and dihydroergotoxine but not by DA. Therefore, hemodynamic effects of ibopamine probably can be ascribed mainly to the stimulation of DA1 and DA2 receptors, whereas its neuroendocrine effects are produced by DA2 receptor stimulation.",
keywords = "Congestive heart failure, DA2 receptor stimulation, Dihydroergotoxine, Dopamine, Ibopamine, Norepinephrine, Systemic hemodynamics",
author = "Marco Metra and Cristina Missale and {Franco Spano}, Pier and {Dei Cas}, Livio",
year = "1995",
language = "English",
volume = "25",
pages = "732--740",
journal = "Journal of Cardiovascular Pharmacology",
issn = "0160-2446",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Dopaminergic drugs in congestive heart failure

T2 - Hemodynamic and neuroendocrine responses to ibopamine, dopamine, and dihydroergotoxine

AU - Metra, Marco

AU - Missale, Cristina

AU - Franco Spano, Pier

AU - Dei Cas, Livio

PY - 1995

Y1 - 1995

N2 - Ibopamine has hemodynamic and neurohumoral effects potentially useful for the treatment of congestive heart failure (CHF), but its mechanism of action is not completely clear. To evaluate the role of dopaminergic receptor stimulation in the hemodynamic and neurohumoral activity of ibopamine, we compared the effects of ibopamine, 100 mg orally (p.o.) with those of dopamine 2, 4, and 6 μg/kg/min intravenously (i.v.) and of the DA2 agonist dihydroergotoxine 6 μg/kg i.v. in 13 patients with chronic CHF [left ventricular ejection fraction (LVEF) ±35%]. All patients underwent right heart Swan-Ganz catheterization with determination of hemodynamic parameters at baseline, after 30 min of infusion of each dose of dopamine (DA) and ±6 h after ibopamine and dihydroergotoxine administration. Blood samples for the assessment of plasma renin activity (PRA), aldosterone, norepinephrine (NE), and epinephrine (Epi) were also obtained. Ibopamine induced a peak 21% increase of cardiac index (CI) with a 23 and 25% increase in stroke volume (SV) and stroke work indexes (SWI), respectively, and an 18% reduction in systemic vascular resistance (SVR). Similar changes were observed after DA infused at the doses of 2 and 4 μg/kg/min, whereas with the dose of 6 μg/kg/min heart rate (HR) increased by 23% and SV index (SVI) did not change further. Dihydroergotoxine administration induced only a significant 9% decrease in mean arterial pressure (MAP), with a 13% reduction in SVR. Plasma NE levels were reduced by 24% after ibopamine and by 20% after dihydroergotoxine; in contrast, DA did not significantly change NE levels at the doses of 2 and 4 μg/kg/min and increased them at 6 μg/kg/min. Plasma aldosterone levels were significantly decreased by all three agents. The effects of ibopamine on systemic hemodynamics are similar to those of DA infused at 2-4 μg/kg/min, whereas the DA2 agonist dihydroergotoxine reduced arterial pressure and SVR. Plasma aldosterone levels were decreased by all three agents, whereas plasma NE levels were reduced by ibopamine and dihydroergotoxine but not by DA. Therefore, hemodynamic effects of ibopamine probably can be ascribed mainly to the stimulation of DA1 and DA2 receptors, whereas its neuroendocrine effects are produced by DA2 receptor stimulation.

AB - Ibopamine has hemodynamic and neurohumoral effects potentially useful for the treatment of congestive heart failure (CHF), but its mechanism of action is not completely clear. To evaluate the role of dopaminergic receptor stimulation in the hemodynamic and neurohumoral activity of ibopamine, we compared the effects of ibopamine, 100 mg orally (p.o.) with those of dopamine 2, 4, and 6 μg/kg/min intravenously (i.v.) and of the DA2 agonist dihydroergotoxine 6 μg/kg i.v. in 13 patients with chronic CHF [left ventricular ejection fraction (LVEF) ±35%]. All patients underwent right heart Swan-Ganz catheterization with determination of hemodynamic parameters at baseline, after 30 min of infusion of each dose of dopamine (DA) and ±6 h after ibopamine and dihydroergotoxine administration. Blood samples for the assessment of plasma renin activity (PRA), aldosterone, norepinephrine (NE), and epinephrine (Epi) were also obtained. Ibopamine induced a peak 21% increase of cardiac index (CI) with a 23 and 25% increase in stroke volume (SV) and stroke work indexes (SWI), respectively, and an 18% reduction in systemic vascular resistance (SVR). Similar changes were observed after DA infused at the doses of 2 and 4 μg/kg/min, whereas with the dose of 6 μg/kg/min heart rate (HR) increased by 23% and SV index (SVI) did not change further. Dihydroergotoxine administration induced only a significant 9% decrease in mean arterial pressure (MAP), with a 13% reduction in SVR. Plasma NE levels were reduced by 24% after ibopamine and by 20% after dihydroergotoxine; in contrast, DA did not significantly change NE levels at the doses of 2 and 4 μg/kg/min and increased them at 6 μg/kg/min. Plasma aldosterone levels were significantly decreased by all three agents. The effects of ibopamine on systemic hemodynamics are similar to those of DA infused at 2-4 μg/kg/min, whereas the DA2 agonist dihydroergotoxine reduced arterial pressure and SVR. Plasma aldosterone levels were decreased by all three agents, whereas plasma NE levels were reduced by ibopamine and dihydroergotoxine but not by DA. Therefore, hemodynamic effects of ibopamine probably can be ascribed mainly to the stimulation of DA1 and DA2 receptors, whereas its neuroendocrine effects are produced by DA2 receptor stimulation.

KW - Congestive heart failure

KW - DA2 receptor stimulation

KW - Dihydroergotoxine

KW - Dopamine

KW - Ibopamine

KW - Norepinephrine

KW - Systemic hemodynamics

UR - http://www.scopus.com/inward/record.url?scp=0028919532&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028919532&partnerID=8YFLogxK

M3 - Article

VL - 25

SP - 732

EP - 740

JO - Journal of Cardiovascular Pharmacology

JF - Journal of Cardiovascular Pharmacology

SN - 0160-2446

IS - 5

ER -